Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to $83.0 million.

  • Ocular Therapeutix's Operating Expenses rose 2269.06% to $83.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $322.0 million, marking a year-over-year increase of 3671.46%. This contributed to the annual value of $322.0 million for FY2025, which is 3671.45% up from last year.
  • According to the latest figures from Q4 2025, Ocular Therapeutix's Operating Expenses is $83.0 million, which was up 2269.06% from $83.2 million recorded in Q3 2025.
  • Ocular Therapeutix's 5-year Operating Expenses high stood at $83.2 million for Q3 2025, and its period low was $27.6 million during Q1 2021.
  • In the last 5 years, Ocular Therapeutix's Operating Expenses had a median value of $35.3 million in 2023 and averaged $47.5 million.
  • In the last 5 years, Ocular Therapeutix's Operating Expenses surged by 72.93% in 2022 and then soared by 9413.5% in 2024.
  • Quarter analysis of 5 years shows Ocular Therapeutix's Operating Expenses stood at $30.4 million in 2021, then increased by 10.14% to $33.4 million in 2022, then rose by 4.23% to $34.9 million in 2023, then skyrocketed by 94.14% to $67.7 million in 2024, then increased by 22.69% to $83.0 million in 2025.
  • Its Operating Expenses was $83.0 million in Q4 2025, compared to $83.2 million in Q3 2025 and $81.1 million in Q2 2025.